The present invention is generally directed to systems and methods for dispensing ingestible tablets.
Increasingly, many consumers are finding themselves ingesting any number of different supplements throughout the day for a variety of reasons. Typically, the consumers manually retrieve the supplement tablets or capsules from their individual packaging and may ingest one or more of the supplement tablets immediately, or may hold onto one or more of the supplement tablets for a later time, for example in a different container. As another example, consumers may meter out their different supplements from individual packaging into individual containers, e.g., one container including all of their supplements for a particular day of the week.
Automated medicine handling systems are known. The automated systems are typically for industrial purposes and include relatively complex robotic mechanisms. What is needed is a portable, personal dispenser capable of dispensing multiple, different types of ingestible tablets that can be readily accessed by a consumer.
In one embodiment, an ingestible tablet includes a front face, a rear face and sides that extend about a periphery of the front and rear faces. A glidant coating may be provided and a groove extends along at least one of the front and rear faces. The groove intersects the periphery at opposite sides and being sized to receive a guide rail of a cartridge for inhibiting rotational movement and maintaining alignment of the ingestible tablet as the ingestible tablet is fed through the cartridge. The groove may have a glidant coating located therein thereby forming a recessed, low friction surface arranged to contact the guide rail of the cartridge.
In another embodiment, a cartridge for holding a plurality of ingestible tablets for a tablet dispenser is provided. The cartridge includes a front wall, a rear wall and side walls extending from the front wall to the rear wall. The front wall, rear wall and sidewalls define a volume for receiving the plurality of ingestible tablets such that the plurality of ingestible tablets may be fed from the volume. A guide rail extends into the volume along a height of the front wall or the rear wall. The guide rail is sized and arranged to slidably engage the plurality of ingestible tablets for inhibiting rotational movement and maintaining alignment of the plurality of ingestible tablets as the plurality of ingestible tablets are fed through the volume.
In another embodiment, a portable tablet dispenser includes a cartridge defining a volume for receiving a plurality of ingestible tablets. The cartridge includes a dispensing end through which the plurality of ingestible tablets are dispensed from the volume and a catch mechanism having a closed configuration that inhibits dispensing of the plurality of ingestible tablets from the volume and an open configuration that allows dispensing of the plurality of ingestible tablets from the volume. A main housing includes a cartridge port that receives the dispensing end of the cartridge. The main housing includes a catch engaging structure arranged and configured to engage the catch mechanism of the cartridge for moving the catch mechanism from the closed configuration to the open configuration.
In another embodiment, a portable tablet dispenser includes a carrier layer including a tablet carrying chamber sized to receive an ingestible tablet. A drop layer is located beneath the carrier layer and includes a tablet receiving opening through which the tablet may pass from the tablet carrying chamber. In a rest configuration, the tablet carrying chamber is in alignment with the tablet receiving opening. In a triggered configuration, the tablet carrying chamber is moved out of alignment with the tablet receiving opening.
In another embodiment, a portable tablet dispenser includes a plurality of cartridges including a first cartridge including a first plurality of ingestible tablets housed therein and a second cartridge including a second plurality of ingestible tablets housed therein. A main housing includes a first cartridge port that receives a dispensing end of the first cartridge and a second cartridge port that receives a dispensing end of the second cartridge. A dispensing mechanism is located in the main housing. The dispensing mechanism is configured to selectively dispense an individual ingestible tablet from one and simultaneously both of the first cartridge and the second cartridge where selection is based on a user input.
The following detailed description of specific embodiments of the present invention can be best understood when read in conjunction with the drawings enclosed herewith.
The embodiments set forth in the drawings are illustrative in nature and not intended to be limiting of the invention defined by the claims. Moreover, individual features of the drawings and invention will be more fully apparent and understood in view of the detailed description.
The following text sets forth a broad description of numerous different embodiments of the present invention. The description is to be construed as exemplary only and does not describe every possible embodiment since describing every possible embodiment would be impractical, if not impossible, and it will be understood that any feature, characteristic, component, composition, ingredient, product, step or methodology described herein can be deleted, combined with or substituted for, in whole or part, any other feature, characteristic, component, composition, ingredient, product, step or methodology described herein. Numerous alternative embodiments could be implemented, using either current technology or technology developed after the filing date of this patent, which would still fall within the scope of the claims. All publications and patents cited herein are incorporated herein by reference.
It should also be understood that, unless a term is expressly defined in this specification using the sentence “As used herein, the term ‘______’ is hereby defined to mean . . . ” or a similar sentence, there is no intent to limit the meaning of that term, either expressly or by implication, beyond its plain or ordinary meaning, and such term should not be interpreted to be limited in scope based on any statement made in any section of this patent (other than the language of the claims). No term is intended to be essential to the present invention unless so stated. To the extent that any term recited in the claims at the end of this patent is referred to in this patent in a manner consistent with a single meaning, that is done for sake of clarity only so as to not confuse the reader, and it is not intended that such a claim term be limited, by implication or otherwise, to that single meaning Finally, unless a claim element is defined by reciting the word “means” and a function without the recital of any structure, it is not intended that the scope of any claim element be interpreted based on the application of 35 U.S.C. §112, sixth paragraph.
As used herein, the term “tablet” refers to a small ingestible mass including a supplement material. The term “supplement material” includes materials commonly referred to as vitamins and supplements and is not meant to exclude medicated materials. Tablets often include a mixture of a supplement material and excipients, often in powder form, pressed and/or compacted into a solid. Exemplary excipients may include binders, disintegrants to promote tablet break-up in the digestive tract; sweeteners or flavors to enhance taste; and/or pigments to make the tablets visually attractive. Coatings such as glidants and lubricants may be provided to promote efficient tabletting. Glidant coatings may refer to any coating which can be used to lower the frictional force of a tablet against a surface. Polymer coatings (which may be a form of glidant coating) may be provided to make the tablet smoother and easier to swallow, to control the release rate of the supplement material, to make the tablet more resistant to the environment and/or to enhance the tablet's appearance.
As used herein, the term “portable” refers to the capability of being carried by hand from one location to another. In some embodiments, a portable device weights about 25 pounds or less, such as about 10 pounds or less, such as about 5 pounds or less and has a dimension (e.g., height and/or width) of no greater than about three feet or less, such as two feet or less, such as one foot or less, such as about 10 inches or less, such as about five inches or less.
I. Introduction
Referring to
II. Tablets
Referring to
In the illustrated embodiment, the grooves 44 and 46 may include a cross-sectional width Wg and a depth Dg. The width Wg may be defined as the maximum distance between sidewalls 48 and 50 of the grooves 44 and 46 along the length of the grooves 44 and 46 and the depth Dg may be defined as the maximum depth from the respective face 32 and 34 to a base 52 of the grooves 44 and 46. In some embodiments, the ratio of the width Wg to the depth Dg is no greater than about 2.5. In some embodiments, the sidewalls 48 and 50 of the grooves 44 and 46 may be slanted inwardly toward each other, forming somewhat V-shaped grooves 44 and 46 that extend inwardly to the base 52. In these embodiments, outer edges 54 and 56 of the sidewalls 48 and 50 may form an angle a that is greater than 90 degrees (e.g., between about 90 degrees and about 150 degrees) with the respective face 32 and 34. In other embodiments, the sidewalls 48 and 50 may be relatively straight with a being about 90 degrees.
The tablets 24 may have a minimum thickness Tmin, e.g., at the one or more grooves 44 and 46 and a maximum thickness Tmax, e.g., adjacent the one or more grooves 44 and 46. In some embodiments, the minimum thickness Tmin is no greater than about 95 percent of the maximum thickness Tmax. In some embodiments, the minimum thickness Tmin is no less than about 50 percent of the maximum thickness Tmax.
The tablets 24 may be formed of a mixture of a supplement material and excipients, in powder form, pressed and/or compacted into a solid. The tablets 24 may include, for example, any one or more of the following: antioxidants (e.g., pomegranate, green tea, vitamins A, C and E, anthocyanidins, catechins, epicatechins, flavanols, flavonoids, free radicals, lutein, lycopene, phenols, proanthocyanidins, procyanidins, zeaxanthin); immune-enhancing ingredients (e.g., black seed, ginseng, probiotics, arabinogalactan, arginine, astragalus, amaranth oil, black currant, colostrum, cat's claw, echinacea, gamma linolenic acid, goldenseal, maitake mushroom, rose hip, shiitake, taurine, thymus extract, vitamins B6, D and E); omega-3 sources (e.g., flax seed, fish oils, English walnuts, soybean oil, linseed oil, olive oil, borage seed oil, canola oil); energy enhancing ingredients (e.g., green tea, rhodiola, B vitamins, carnitine, creatine, ginkgo biloba, ginseng, guarana extracts, inositol, maltodextrin, taurine); stress-relief and mental health ingredients (e.g., SAMe (s-adenosyl-L-methionine), kava kava (piper methysticum), sage, St. John's Wort, valerian (valerian officinalis), 5-hydroxytryptophan (5-HTP), dehydroepiandoseterone (DHA), phenylalanine, melatonin, chamomile, creatine, L-theanine); and joint and bone health ingredients (e.g., glucosamine, calcium, chondroitin, willow bark, 5-HTP, avocado/soybean unsaponifiables, borage seed oil, chlorella, devil's claw, omega-3 fatty acids (see sources above), rose hip, SAMe, vitamin D).
In some embodiments, the tablets 24 may be coated with one or more coatings 60. For example, an enteric coating and a delayed release coating may be applied to the tablets 24. Examples of enteric coating materials include ethylcellulose, pectin, guar gum, methyl methacrylate and cellulose acetate phthalate. Examples of delayed release materials include ethylcellulose, methylcellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, pectin, guar gum and xanthan gum. Various other coating materials include methylmethacrylate, methacrylic acid copolymer, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methyl acetate succinate, cellulose acetate phthalate, polyethylene glycol, triethylacetate, glyceryl triacetate, acetyltriethylcitrate, dibutyl sebacate, dibutyl phthalate, glycerol, triacetin, acetylated monoglyceride, oleic acid and stearic acid. Coatings (e.g., glidant coatings) may be used for ease of swallowing. Flavors may also be added to the coatings, such as mint flavors, tart flavors, etc. Such flavors may provide benefits to the consumers, such as stomach relief and certain perception benefits such as reduced grittiness and tablet size.
The tablets 24 may be any of a variety of colors. In some embodiments, it may be desirable that tablets housed within a given cartridge 22 are of a certain color, while tablets within a different cartridge 22 are of a different color. This may be useful to associate certain colors of tablets 22 with certain functions; for example, a reddish-colored tablet 22 may be associated with heart health making it easier for the user to select the desired tablet 22 for dispensing. It will be well understood that tablets housed within a given cartridge 22 or within multiple cartridges 22, or within a tablet dispenser 10, may be of same or different colors. Selection of colors and manufacture of tablets of any given desired color are well within the capabilities of the ordinarily skilled artisan.
In some embodiments, the tablets 24 may include medicated materials such as decongestants and/or other medicated materials. Example decongestants include: oxymetazoline, phenylephrine, xylometazoline, naphazoline, 1-desoxyephedrine, ephedrine, propylhexedrine, pseudoephedrine, and phenylpropanolamine. Example anticholinergics include: ipratropium, chlorpheniramine, brompheniramine, diphenhydramine, doxylamine, clemastine, and triprolidine. Common analgesics, anti-inflammatories and antipyretics include: ibuprofen, ketoprofen, diclofenac, naproxen, acetaminophen, and aspirin. Example antivirals include: amantidine, rimantidine, pleconaril, zanamivir, and oseltamivir. Examples of antitussives include codeine, dextromethorphan, chlophedianol and levodropropizine. Examples of expectorants include guaifenesin. Examples of mucolytics include ambroxol and N-acetylcysteine. Examples of antihistamines include diphenhydramine, doxylamine, triprolidine, clemastine, pheniramine, chlorpheniramine, brompheniramine, loratadine, cetirizine and fexofenadine.
Compositions included in the tablets 24 can comprise a wide range of additional pharmaceutical actives. Nonlimiting examples include antitussives, antihistamines, non-sedating antihistamines, decongestants, expectorants, analgesics, antipyretic anti-inflammatory agents, local anesthetics, anti-inflammatory agents, demulcents, herbal remedies, vitamins, supplements, antioxidants, natural ingredients, minerals, energy boosting ingredients, sleep aids and immune system boosting, tea extract, antioxidant, amino acid, enzyme, prebiotic, probiotic, andrographis extract, 1-tryptophan, Allium sativum, anticholinergics, antivirals, mucolytics, and combinations thereof.
Examples of decongestants include: oxymetazoline, phenylephrine, xylometazoline, naphazoline, 1-desoxyephedrine, ephedrine, propylhexedrine, pseudoephedrine, and phenylpropanolamine. Examples of anticholinergics include: ipratropium, chlorpheniramine, brompheniramine, diphenhydramine, doxylamine, clemastine, and triprolidine. Common analgesics, anti-inflammatories and antipyretics include: ibuprofen, ketoprofen, diclofenac, naproxen, acetaminophen, and aspirin. Examples of antivirals include: amantidine, rimantidine, pleconaril, zanamivir, and oseltamivir. Examples of antitussives include codeine, dextromethorphan, chlophedianol and levodropropizine. Examples of expectorants include guaifenesin. Examples of mucolytics include ambroxol and N-acetylcysteine. Examples of antihistamines include diphenhydramine, doxylamine, triprolidine, clemastine, pheniramine, chlorpheniramine, brompheniramine, loratadine, cetirizine and fexofenadine.
Nonlimiting examples of additional pharmaceutical actives include but are not limited to, pyrilamine, promethazine, oxycodone, hydrocodone, carbinoxamine, caffeine, benzonatate, pheniramine, fentanyl, azatedine, desloratadine, carbamazepine, buprenorphine, hydromorphone, indomethacin, oxymorphone, phenol, codeine, mesalamine, dichlophenac, sulindac, beclomethaxone, meloxicam, fenoproten, mometasone, menthol, benzocaine, dipyridamole, methscopolamine, the free and the addition salt forms, chamomile, passion flower, Vitamin C, Vitamin D, B Vitamins, echinacea, melatonin, green tea, curcumin, zinc, selenium, calcium, guarana, probiotics and mixtures thereof.
The compositions may comprise an amount of at least one additional pharmaceutical active in the range of about zero (0) mg to about 1,000 mg of each of at least one additional pharmaceutical active, alternatively from about 2.5 mg to about 750 mg, and alternatively from about 5 mg to about 650 mg of each of at least one additional pharmaceutical active, all per dose of the composition.
The compositions may comprise an amount of additional pharmaceutical active in the range of about 0% to about 20%, alternatively 0.0001% to about 15%, alternatively from about 0.001% to about 10%, and alternatively from about 0.01% to about 5%, all by weight of the composition.
As indicated above, the composition can comprise an excipient. The composition can comprise from about 0.1% to about 99% of the excipient, by weight of the composition, alternatively from about 0.25% to about 70%, alternatively from about 0.5% to about 70%, alternatively from about 2% to about 70%, alternatively from about 3% to about 40%, alternatively from about 5% to about 30%, alternatively from about 6% to about 25% of the excipient, by weight of the composition. Nonlimiting examples of excipients include of microcrystalline cellulose, dicalcium phosphate, stearic acid, magnesium stearate, corn starch, lactose, sodium croscarmellose, sodium starch glycolate, polyvinylpyrollidone, gelatin and combinations thereof. When the excipient is magnesium stearate, the level of magnesium stearate present may be at least 0.1%, alternatively less than about 0.5%, alternatively less than about 0.25%, by weight of the composition. By keeping the level of magnesium stearate at least about 0.1%, aids to prevent darkening of the composition caused by the presence of certain sensitive ingredients such as doxylamine and/or phenylephrine.
The composition may comprise a chelating agent. Non-limiting examples of chelating agents include but are not limited to the salts of disodium and calcium salts of ethylene diamine tetraacetic acid (EDTA), tetrasodium EDTA, sodium hexametaphosphate (SHMP), citric acid, phosphoric acid, di(hydroxyethyl)glycine, 8-hydroxyquinoline, and mixtures thereof. Trivalent metal chelating agents such as galactomannans complexed with iron may also be useful. Wherein the compositions herein comprise a chelaing agent, the compositions may optionally comprise from about 0.0001% to about 1% of the chelating agent, alternatively from about 0.001% to about 0.5%, and alternatively from about 0.01% to about 0.3% of the chelating agent, all by weight of the composition.
The composition may comprise a sweetener to provide sweetness and aid in the taste masking of a pharmaceutical active(s) and/or sensitive ingredients. The sweeteners of the present invention can be artificial sweeteners and/or natural sweeteners. Non-limiting examples of artificial sweeteners are selected from the group consisting of sodium saccharine, acesulfame potassium, sucralose, aspartame, monoammonium glycyrrhizinate, neohesperidin dihydrochalcone, thaumatin, neotame, cyclamates, and mixtures thereof. Nonlimiting examples of natural sweeteners include sucrose, fructose, glucose, glycerin, sorbitol, maltitol, and mannitol and combinations thereof.
The compositions can comprise a wide range of optional ingredients. Nonlimiting examples of optional ingredients include antimicrobial metal salts, optional mildness enhancers, optional stabilizers, abrasives, antioxidants, biological additives, chemical additives, colorants, coolants, chelants, denaturants, drug astringents, emulsifiers, external analgesics, film formers, fragrance compounds, humectants, opacifying agents, plasticizers, preservatives, propellants, reducing agents, solvents, foam boosters, hydrotropes, solublizing agents, suspending agents (non-surfactant), a solvent, viscosity increasing agents (aqueous and non-aqueous), sequestrants, vitamins, antioxidants, buffers, keratolytics, and the like, and combinations thereof. The optional ingredient may be selected from the group consisting of solvents, a chelant, a preservative, a fragrance, buffer, antimicrobial metal salts and combinations thereof. Nonlimiting examples of antimicrobial metal salts include zinc, iron, copper, silver, tin, bismuth, and combinations thereof. Nonlimiting examples of preservatives include but are not limited to benzoalkonium chloride, EDTA, benzyl alcohol, potassium sorbate, parabens, and mixtures thereof.
Unless otherwise specified, the compositions may optionally comprise one or more given optional ingredients at concentrations ranging from about 0.001% to about 99%, alternatively from about 0.01% to about 80%, alternatively from about 0.01% to about 50%, alternatively from about 0.01% to about 10%, all by weight of the composition.
III. Cartridges
Referring to
A catch structure 78 may be provided at the dispensing end 77. The catch structure 78 may include an outwardly extending portion 80 that extends outwardly, away from the volume 64 and a finger portion 82 that extends away from the outwardly extending portion 80. The outwardly extending portion 80 may provide a connection between the finger portion 82 and one or more of the front wall 66, back wall 68 and/or side walls 70 and 72. In the illustrated embodiment, the outwardly extending portion 80 cantilevers the catch structure 78 to the front wall 66. A catch member 84 may be located at an end of the finger portion 82 that extends into and/or beneath the volume 64. The catch member 84 may be sized and located to inhibit dispensing of tablets 24 by blocking at least a portion of the end 77. In some embodiments, the catch member 84 may extend into the volume 64 a length L that is at least about 10 percent of a width W of the volume 64 measured between the front wall 66 and the back wall 68. In some embodiments the length L may be at least about 20 percent of the width W. In some embodiments, the length L may be no more than about 80 percent of the width W, such as no more than about 50 percent of the width W. In some embodiments, the length L may be between about 5 percent and about 80 percent of the width W, such as between about 10 percent and about 50 percent of the width W.
Referring particularly to
The cartridges 22 may be formed using any suitable method or combination of methods such as molding and/or machining In some embodiments, the cartridges 22 are formed of a molding process where a first portion 100 including the front wall 66, sidewalls 70 and 72, end wall 76 and catch structure 78 is formed separately from a second portion 102 including the back wall 68. The first portion 100, once formed, may be attached to the second portion 102 at a flange portions 104 and 106 that extend along the periphery of the first portion 100 and the second portion 102, for example, using an adhesive, welding, etc. In some embodiments, the catch member 84 may be formed separately from the catch structure 78 and then attached thereto at the position illustrated by
In some embodiments, one or more of the cartridges 22 may be filled with tablets 24 at a filling location that is remote from the consumer. The cartridges 22 may be sealed in packaging and then transported to the customer or to a retail location. In some embodiments, a foil or other temporary barrier may be placed over the open end of the cartridge 22 that can be removed by the consumer. In some embodiments, tamper evident packaging and/or features making the package difficult for young children to open may be provided. The cartridges 22 may be refillable and/or may be disposable. Any suitable materials may be used for forming the cartridges including food grade materials. Exemplary materials for forming the cartridge 22 may include, but not limited to, polyethylene terephalate (PET), polypropylene, polyethylene, polyvinylchloride, etc. The cartridge 22 may be opaque or transparent or a combination of opaque in some areas and transparent in others.
In some embodiments, the cartridges 22 may house tablets without grooves and or multiple columns of tablets. For example, round pills may be housed by the cartridges in some embodiments. In some embodiments, the cartridges 22 may be used to transport and dispense tablets 24 independently of the tablet dispenser 10.
The cartridges 22 may be transparent, opaque, or of any other appearance. In some embodiments, it may be desirable that at least one or all of the cartridges are transparent to some extent. For example, wherein tablets 22 housed within a given cartridge are of a certain color to associate a functional benefit as described herein above, some extent of transparency will be desirable such that the user can see the color of the tablets, thereby aiding a dispensing decision. It is well within the skills of the ordinary artisan to design and manufacture cartridges having the desired appearance.
III. Tablet Dispenser
Referring back to
Referring now to
The upper housing 16 includes the body 26, a button housing 122 and a liner 125 where the button housing 122 and liner 125 are connected to the body 26. Referring to
Referring to
Referring to
Referring to
Referring to
Referring next to
Each cartridge receiving area 202a-f may include a tablet receiving opening 208a-f. The tablet receiving openings 208a-f may generally be aligned with associated cartridge ports 110a-f such that the tablet receiving openings 208a-f may receive tablets 24 dispensed from the cartridges 22 located in the cartridge ports 110a-f. A catch engaging structure 210a-f may be provided adjacent the tablet receiving openings 208a-f. The catch engaging structures 210a-f (e.g., ridges or ramps) may be shaped and arranged to engage the catch structure 78 to move the catch member 84 away from the volume 64 of the respective cartridge (e.g., as the dispensing end 77 of the cartridge 22 is inserted into the cartridge receiving area 202a-f through the cartridge ports 110a-f) such that tablets 24 may be readily dispensed from the cartridge 22.
Referring to
Actuation of the selector switches 115a-f pivots their associated latch plates 214a-f between latched and unlatched configurations. As can be seen by
Referring to
Referring to
Referring to
Referring to
In the initial, unactuated position, the tablet carrying chambers 226a-f of the carrier layer are out-of-alignment (i.e., out-of-phase) with the tablet receiving openings 208a-f of the bottom switch housing layer 174. In some embodiments, the tablet carrying chambers 226a-f may be aligned (i.e., in phase) with the tablet receiving openings 256a-f of the drop layer 178 in the initial, unactuated position. As can be seen by
A drawer or removable container assembly may be connected to or part of the main housing 14 (
Referring now to
In some embodiments, the tablets 24 may be gravity fed through the tablet dispenser 10. In such embodiments, it may be desirable to provide a relatively low coefficient of friction between the tablets 24 and the cartridges 22 as the tablets 24 slide along the guide rails 86, 88 of the cartridges 22. In some embodiments, the frictional force between the tablet 24 and the cartridge 22 may be less than the force due to gravity on the tablet 24 so that gravity exerts a greater force than the force of friction of the tablet 24 thereby allowing the tablet 24 to slide through the cartridge 22 and be dispensed under the force of gravity. In some embodiments, the frictional force may be less than about 80 percent of the force of gravity, for example, so that the tablet 24 may drop through the cartridge at a suitable or preselected rate. The friction force between the tablet 24 and the cartridge 222 may be lowered, for example, using any suitable glidant coating applied to the tablet 24 and/or the cartridge 22. In some embodiments, a glidant coating may be applied to the tablet 24 and/or the cartridge 22 to provide a relatively even distribution of friction forces at opposite ends of the tablet 24 as the tablet 24 slides through the cartridge 22 to minimize or reduce rotational forces on the tablet 24 as it drops through the cartridge 22. In some embodiments, the tablets 24 may be pushed (or otherwise moved) through the cartridges 22 by another applied force. For example,
Referring to
In some embodiments, the tablet dispensers may include a power source, such as a battery, and/or may be connected to a power source. The tablet dispensers may be programmed to provide reminders, e.g., when and/or which tablets 24 to take and/or whether tablets 24 have already been taken and include memory to storing such tablet information. The tablet dispensers may include a display, for example, displaying the time and/or tablet information, alarms, etc. While tablets 24 are primarily discussed above, other pill-types may be used with the tablet dispensers, such as capsules. The tablets 24 may or may not have grooves. In some embodiments, the tablet dispensers may receive information from a user and/or retrieve information automatically from a network or Internet connection. In some embodiments, a system of multiple tablet dispensers may be utilized, e.g., for various members of a household and the tablet dispensers may be able to communicate tablet information and/or other data between tablet dispensers, e.g., through a wired or wireless connection.
The tablet dispenser 10 or any component thereof, may be transparent, opaque, or of any other appearance. In some embodiments, it may be desirable that at least one component of the tablet dispenser 10 is transparent to some extent. For example, wherein tablets 24 housed within a given cartridge 22 are of a certain color to associate a functional benefit as described herein above, and the cartridge 22 housing such tablets are to some extent of transparent, it may also be desirable that certain portions of the tablet dispenser 10 (for example, upper housing 16) are to some extent transparent such that the user can see the color of the tablets prior to dispensing, thereby aiding a dispensing decision. It is well within the skills of the ordinary artisan to design and manufacture tablet dispensers 10 having the desired appearance.
Referring to
All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this written document conflicts with any meaning or definition of the term in a document incorporated by reference, the meaning or definition assigned to the term in this written document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
This application claims priority to U.S. Provisional Application No. 61,291,500, filed on Dec. 31, 2009.
Number | Date | Country | |
---|---|---|---|
61291500 | Dec 2009 | US |